Patients with rare diseases face unique challenges. Often, there may be no FDA approved treatments for them, or the patient population with an orphan disease is very small – it may be difficult to find clinical trials developing medicine for their diseases. For this reason, the FDA is expanding the use of the Reagan-Udall Foundation’s Expanded Access Navigator tool to include rare or orphan diseases. After this expansion, patients and their physicians will have the ability to use the Navigator to explore options for pre-approval access to drugs. For more on this, please read the announcement by FDA Commissioner Scott Gottlieb, MD.
- How can our society study and regulate the offerings of popular, but unproven, regenerative medicine?
- One patient’s story: How WCGF helped speed approval for experimental treatment
- How did physicians use a discovery from a recent #clinicaltrial to save the life of a boy with a dangerous skin condition?
- How is the FDA widening the scope of the Reagan Udall Expanded Access Navigator to assist patients with rare or orphan diseases?
- How can you further WCGF’s mission to educate, include and provide access?